SCNI: חוב לטווח קצר של החברה Scinai Immunotherapeutics

This chart of Scinai Immunotherapeutics (SCNI) asset value demonstrates the 0.00 metric. Share price action remains independent of the broader economy, as business success is determined by the results of nanobody tests for gastrointestinal therapy. The model relies on the efficiency of the NanoAb system and the volume of antibody production in rodent cells. The company's innovations involve creating inhalable biologics based on llama antibodies to combat COVID and influenza.

For Scinai Immunotherapeutics (SCNI), which is developing CDMO services and proprietary immunotherapy research, an analysis of short-term balance sheet liabilities allows for an assessment of the operating model's liquidity. This indicator aggregates all loans with a maturity of up to one year, measuring the issuer's ability to service urgent payments without compromising R&D, where a reduction in debt may either signal financial recovery or indicate investment stagnation.